IBJNews

Indiana life sciences companies capture more venture capital money in first half of 2010

Back to TopCommentsE-mailPrintBookmark and Share
On The Beat Industry News In Brief

Venture dollars for Indiana life sciences companies are still few, but the flow of deals is picking up.

Nine Hoosier companies scored investments totaling $10.4 million during the first six months of the year, according to IBJ research and data from Cleveland-based BioEnterprise, a life sciences business development group.

During the same period a year ago, just four companies secured venture capital, for a total of $8.9 million.

Indiana’s total dollars ranked it a lowly ninth out of 11 Midwestern states tracked by BioEnterprise. But its number of deals ranked second, behind only Ohio.

The trend of smaller deals has been consistent across the Midwest for the past 18 months. For example, five Indiana companies attracted investments of $750,000 or less. The smallest deal was Warsaw-based OrthoPediatrics’ funding of $50,000.

“The number of companies attracting financing remains higher. This is primarily due to increasing seed and angel-stage activity across the Midwest,” said Baiju R. Shah, CEO of BioEnterprise, in a statement.

Through the end of June, total venture capital invested in Midwestern life sciences companies was $412 million, up 2 percent from the same period a year ago but down 44 percent from three years ago.

Indiana’s venture haul is down more than 80 percent this year compared with the same date three years ago.

There were 75 Midwestern deals during the first half of the year, down slightly from 81 a year ago but still higher than in 2007.

Indiana had twice as many deals this year than at the same time in 2007. The companies scoring investments included Indianapolis-based Fast Diagnostics, with $2.75 million; Indianapolis-based FlowCo, with $2 million; and Indianapolis-based PolicyStat, with $1.15 million.

Outside of Indianapolis, West Lafayette-based QuadraSpec pulled in $2.33 million. The company has since changed its name to Perfinity Biosciences Inc.

BioEnterprise credited Indiana with $9.2 million raised by CoLucid Pharmaceuticals. The drug discovery firm started in Indianapolis, studying a drug bought from Eli Lilly and Co. But it now makes its headquarters in North Carolina’s Research Triangle Park. Therefore, IBJ excluded those dollars from its calculations.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. By Mr. Lee's own admission, he basically ran pro-bono ads on the billboard. Paying advertisers didn't want ads on a controversial, ugly billboard that turned off customers. At least one of Mr. Lee's free advertisers dropped out early because they found that Mr. Lee's advertising was having negative impact. So Mr. Lee is disingenous to say the city now owes him for lost revenue. Mr. Lee quickly realized his monstrosity had a dim future and is trying to get the city to bail him out. And that's why the billboard came down so quickly.

  2. Merchants Square is back. The small strip center to the south of 116th is 100% leased, McAlister’s is doing well in the outlot building. The former O’Charleys is leased but is going through permitting with the State and the town of Carmel. Mac Grill is closing all of their Indy locations (not just Merchants) and this will allow for a new restaurant concept to backfill both of their locations. As for the north side of 116th a new dinner movie theater and brewery is under construction to fill most of the vacancy left by Hobby Lobby and Old Navy.

  3. Yes it does have an ethics commission which enforce the law which prohibits 12 specific items. google it

  4. Thanks for reading and replying. If you want to see the differentiation for research, speaking and consulting, check out the spreadsheet I linked to at the bottom of the post; it is broken out exactly that way. I can only include so much detail in a blog post before it becomes something other than a blog post.

  5. 1. There is no allegation of corruption, Marty, to imply otherwise if false. 2. Is the "State Rule" a law? I suspect not. 3. Is Mr. Woodruff obligated via an employment agreement (contractual obligation) to not work with the engineering firm? 4. In many states a right to earn a living will trump non-competes and other contractual obligations, does Mr. Woodruff's personal right to earn a living trump any contractual obligations that might or might not be out there. 5. Lawyers in state government routinely go work for law firms they were formally working with in their regulatory actions. You can see a steady stream to firms like B&D from state government. It would be interesting for IBJ to do a review of current lawyers and find out how their past decisions affected the law firms clients. Since there is a buffer between regulated company and the regulator working for a law firm technically is not in violation of ethics but you have to wonder if decisions were made in favor of certain firms and quid pro quo jobs resulted. Start with the DOI in this review. Very interesting.

ADVERTISEMENT